RT Journal Article SR Electronic T1 Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Cancers Identifies KMT2C as a Potential Tumor Suppressor JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.08.24.21262521 DO 10.1101/2021.08.24.21262521 A1 Machnicki, Marcin M. A1 Rzepakowska, Anna A1 Janowska, Joanna I. A1 Pepek, Monika A1 Krop, Alicja A1 Pruszczyk, Katarzyna A1 Stawinski, Piotr A1 Rydzanicz, Malgorzata A1 Grzybowski, Jakub A1 Gornicka, Barbara A1 Wnuk, Maciej A1 Ploski, Rafal A1 Osuch-Wojcikiewicz, Ewa A1 Stoklosa, Tomasz YR 2021 UL http://medrxiv.org/content/early/2021/08/30/2021.08.24.21262521.abstract AB Hypopharyngeal cancer represents one of worst types of head and neck tumors with only few studies focusing on the genomic profile of this type of cancer. Using targeted next-generation sequencing we analyzed 48 HPV-negative tumor samples including 23 originating from hypopharynx, and 25 from larynx. Among genes previously described as significantly mutated, TP53, FAT1, NOTCH1, KMT2C and CDKN2A were found to be most frequently mutated. We also found that more than three-fourths of our patients harbored candidate actionable or prognostic alterations in genes belonging to RTK/ERK/PI3K, cell-cycle and DNA-damage repair pathways. Using previously published data we compared 67 hypopharyngeal cancers to 595 head and neck cancers from other sites and found no prominent differences in mutational frequency except for CASP8 and HRAS genes. Since we observed relatively frequent mutations of KTM2C (MLL3) in our dataset, we analyzed their role in vitro by generating KMT2C-mutant hypopharyngeal cancer cell line FaDu with CRISPR-Cas9. We demonstrate that KMT2C loss-of-function results in increased colony formation and proliferation, in concordance with its previously published results. In summary, our results show that mutational profile of hypopharyngeal cancers might be similar to the one observed for other head and neck cancers with respect to minor differences and includes multiple candidate actionable and prognostic genetic alterations. We also demonstrate for the first time that KMT2C gene may play a role of tumor suppressor in head and neck cancer, which opens new possibilities in the search for new targeted treatment approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Polish National Science Centre, grant number 2013/09/N/NZ2/01354. MMM and MP were supported by Postgraduate School of Molecular Medicine, Medical University of Warsaw.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Medical University of WarsawAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in this study are available in supplementary materials.